CVS Health price target raised to $143 from $130 at Jefferies

Jefferies analyst Brian Tanquilut raised the firm’s price target on CVS Health (CVS) to $143 from $130 and keeps a Buy rating on the shares after the company’s "solid" Q4 report and deal to acquire Oak Street Health (OSH). The firm believes that EPS growth should accelerate at CVS post-2024 as growth should benefit from increasing earnings contribution from Oak Street and Signify as well as synergies realized across CVS’ other business lines. CVS is proving the resilience of its businesses while the valuation and cash generation "remain compelling," the firm tells investors.